

# HLA-DR Monoclonal Antibody (LN3), PerCP-Cyanine5.5, eBioscience™

<b>Product Details</b>	
Size	100 Tests
Species Reactivity	Human
Published Species	Human
Host/Isotype	Mouse / IgG2b, kappa
Recommended Isotype Control	Mouse IgG2b kappa Isotype Control (eBMG2b), PerCP-Cyanine5.5, eBioscience™
Class	Monoclonal
Туре	Antibody
Clone	LN3
Conjugate	PerCP-Cyanine5.5
Excitation/Emission Max	489/679 nm
Form	Liquid
Concentration	5 μL/Test
Purification	Affinity chromatography
Storage buffer	PBS, pH 7.2, with 0.2% BSA
Contains	0.09% sodium azide
Storage conditions	4° C, store in dark, DO NOT FREEZE!
RRID	AB_10718537

Applications	Tested Dilution	Publications
Flow Cytometry (Flow)	5 μL (0.015 μg)/Test	33 Publications

#### **Product Specific Information**

Description: The LN3 mAb reacts with the human major histocompatibility complex (MHC) class II, HLA-DR. HLA-DR is expressed on the surface of human antigen presenting cells (APC) including B cells, monocytes, macrophages, DCs, and activated T cells. HLA-DR is a heterodimeric transmembrane protein composed of alpha and beta subunits and plays an important role in the presentation of peptides to CD4^+ T lymphocytes.


Applications Reported: This LN3 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This LN3 antibody is offered in 2 formats: -  $\mu g$  size: has been tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at less than or equal to 0.015  $\mu g$  per test. A test is defined as the amount ( $\mu g$ ) of antibody that will stain a cell sample in a final volume of 100  $\mu L$ . Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. - test size: has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5  $\mu L$  (0.015  $\mu g$ ) per test. A test is defined as the amount ( $\mu g$ ) of antibody that will stain a cell sample in a final volume of 100  $\mu L$ . Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.

Excitation: 488 nm; Emission: 695 nm; Laser: Blue Laser.


Filtration: 0.2 µm post-manufacturing filtered.

#### Product Images For HLA-DR Monoclonal Antibody (LN3), PerCP-Cyanine5.5, eBioscience™



#### HLA-DR Antibody (45-9956-42)

Staining of human peripheral blood cells. As expected based on known relative expression patterns, HLA-DR clone LN3 stains monocytes and a subset of lymphocytes (B cells) but does not stain granulocytes. Details: Normal human whole blood was surface stained with HLA-DR (clone LN3). After staining, red blood cells were lysed using 1-step Fix/Lyse Buffer. Cells in the lymphocyte (purple histogram), monocyte (orange histogram), or granulocyte (blue histogram) gates were used for analysis of HLA-DR staining. {RE}



#### HLA-DR Antibody (45-9956-42) in Flow

Staining of normal human peripheral blood cells with Mouse IgG2b K Isotype Control PerCP-Cyanine5.5 (Product # 45-4732-82) (open histogram) or Anti-Human HLA-DR PerCP-Cyanine5.5 (filled histogram). Cells in the lymphocyte gate were used for analysis.

#### View more figures on thermofisher.com

#### **□ 33 References**

#### Flow Cytometry (33)

#### Oncoimmunology

## Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.

"45-9956-42 was used in Flow cytometry/Cell sorting to engineer a tri-specific antibody-based molecule that stimulates intratumoral 4-1BB and blocks PD-L1/PD-1 signaling without systemic toxicity and with clinically favorable pharmacokinetics."

Authors: Warmuth S,Gunde T,Snell D,Brock M,Weinert C,Simonin A,Hess C,Tietz J,Johansson M,Spiga FM,Heiz R, Flückiger N,Wagen S,Zeberer J,Diem D,Mahler D,Wickihalder B,Muntwiler S,Chatterjee B,Küttner B,Bommer B,Yaman Y,Lichtlen P,Urech D

### **Year** 2022

Species Human

#### Heliyon

#### Immunometabolic analysis shows a distinct cyto-metabotype in Covid-19 compared to sepsis from other causes.

"45-9956-42 was used in Flow cytometry/Cell sorting to support the hypothesis that IFN- -PD-L1 axis might be involved in the cytokine release syndrome typical of severe Covid-19 and the phenomenon persisted through multiple pandemic waves despite use of immunomodulation."

Authors: Trovato FM,Mujib S,Jerome E,Cavazza A,Morgan P,Smith J,Depante MT,O'Reilly K,Luxton J,Mare T,Napoli S, McPhail MJ

**Year** 2022

Species Human

View more Flow references on thermofisher.com

#### More applications with references on thermofisher.com

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPERESS OR IMPLEA REPRESS OR IMPLEA REGRANTED INITY, IMPLIED WARRANTIES, EXPERESS OR IMPLEA REPRESS OR IMPLEAD IN INFINITY ("INFINITY PROPOSE"). AND ANY PARTICULAR WARRANTIES, EXPERESS OR IMPLEAD IN INFINITY PROPOSED, OR NON INFINITY PROPOSED, OR NON HERRIS EXPERESS OR IMPLEAD IN INFINITY PROPOSED, OR NON HERRIS EXPENSED OR INFINITY PROPOSED, OR NON HERRIS EXPENSED OR INFINITY PROPOSED, OR NON HERRIS EXPENSED OR INFINITY PROPOSED IN INFINITY PROPOS